Refill intervals on every line
The catalogue prints a refill interval beside each product: monthly, every two months, every three months, every ten weeks. That is a small habit with a large effect, because it lets a reader tell a per-month figure from a per-quarter one across the whole shelf without opening every product page.
Both GLP-1 lines are marked as having monthly and quarterly options available, which is why their figures are recorded here as monthly rates rather than as unit prices.
A starting figure with no dose attached
Both GLP-1 prices are prefixed with the seller's own word for a floor. Neither carries a dose, so nothing on the site says what a maintenance month costs or how far the figure moves as the dose climbs.
The entry figures are genuinely low relative to the roster, and that is worth something. But a floor with no ceiling is the least useful shape a price can take for someone planning a course of treatment, and it is the shape both of these take.
The GLP-1 lane is two lines in a hardware store
The catalogue is dominated by recovery peptides, growth-hormone secretagogues, hormone creams and inserts, and cognitive compounds. Weight management is not a programme here; it is two SKUs.
The consequence is that nothing on the site documents titration review, side-effect management, or what supervision a patient gets between refills. A reader who wants a supervised programme is buying from a catalogue that does not describe one.
Nothing named
The pharmacy appears only as a category in a comparison table on the homepage and is never named. No prescribing clinician or medical director is identified. No list of states served appears anywhere we read. Nothing states whether a membership applies.
The operating company is named in the footer, which is more than several sellers here manage, and it is what allowed the FDA screening to be run against an entity rather than only against a brand.
Magnolia Regenerative Medicine's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/mofrom, per month — the sellers own starting figure; the listing states monthly and quarterly options are available and does not say which dose the figure covers | September 2026source |
| Tirzepatide (compounded) | $179/mofrom, per month — the sellers own starting figure; the listing states monthly and quarterly options are available and does not say which dose the figure covers | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See Magnolia Regenerative Medicine's current price →Good fit if
- Readers shopping a broad peptide catalogue who want the GLP-1 line priced on the same terms as everything else on it.
- Patients who want a refill interval stated beside every product rather than assumed.
- Anyone drawn by a low entry figure who understands it is a floor rather than a rate.
- Readers already buying hormone or recovery products who would rather consolidate than add a second supplier.
Look elsewhere if
- Anyone who needs to know what the maintenance dose costs, which the site never says.
- Patients who want a documented, supervised weight-management programme rather than two catalogue lines.
- Readers who need the compounding pharmacy named.
- Anyone who must confirm their state is served before starting.
How this review was verified
- Read the weight-loss listing and the product catalogue at their source URLs and logged both GLP-1 figures with the date they were read.
- Carried the seller's own starting-price language into each qualifier rather than presenting either figure as a flat rate.
- Used the refill interval printed beside each catalogue line to decide that both GLP-1 figures are monthly rates.
- Recorded the pharmacy, prescriber, state and membership positions as gaps rather than inferring any of them.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter for the brand or the operating company.